Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications, for both preclinical and clinical research:
In the past 5-10 years, OAI has become an established imaging modality for in vivo preclinical research. Based on its unique ability to differentiate endogenous chromophores and exogenous probes, a wide variety of applications has been successfully explored.
Following the success of OAI in preclinical research, the technology has already transitioned into clinical research use. Key areas of interest include oncology, inflammation and fibrosis. Results obtained so far support a bright future for OAI in clinical diagnosis.
Munich, DE – Medical device company iThera Medical announces successful funding of the Horizon Europe technology innovation project FRONTIER. Under the EIC Accelerator program, Europe’s
Imaging device company iThera Medical announces the launch of its new inVision TRIO preclinical optoacoustic imaging system. The inVision TRIO is the first imaging system
16.02.2022 – 19.02.2022 // Vienna (Austria)
15.03.2022 – 18.03.2022 // Thessaloniki (Greece)
05.07.2022 – 09.07.2022 // Brussels (Belgium)
If you have any questions about our technology, applications or products, don’t hesitate to get in touch.
